# Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML

> **NCT07493408** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The University of Hong Kong** · enrollment: 45 (estimated)

## Conditions studied

- Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)
- Blastic Transformation of Chronic Myeloid Leukemia
- Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL)
- Haematopoietic Stem Cell Transplant, Allogeneic

## Interventions

- **DRUG:** Asciminib add-on
- **DRUG:** Imatinib
- **DRUG:** Dasatinib
- **DRUG:** Nilotinib

## Key facts

- **NCT ID:** NCT07493408
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-30
- **Primary completion:** 2035-12-31
- **Final completion:** 2037-12-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-03-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07493408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07493408, "Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07493408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*